Nestle CEO eyes growth in health products amid Covid crisis          

Nestle last month agreed to buy Aimmune Therapeutics for $2.6bn (€2.2bn) in its biggest push yet into health science, adding a promising peanut allergy treatment to its offering. File picture

Nestle expects sales of its health nutrition business to double from five years ago as the Swiss company expands in personalised supplements and allergy treatments, chief executive Mark Schneider said.

Revenue will reach about 4 billion Swiss francs (€3.7bn) by the end of 2021, Mr Schneider said in an interview with Bloomberg Television.